Visual field profile of optic neuritis: A final follow-up report from the optic neuritis treatment trial from baseline through 15 years

Archives of Ophthalmology

Volumn 128, Issue 3, 2010, Pages 330-337

  Keltner, John L ^a,b   Johnson, Chris A ^c   Cello, Kimberly E ^a   Dontchev, Mariya ^d   Gal, Robin L ^d   Beck, Roy W ^d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF IOWA   (United States)

^d JAEB CENTER FOR HEALTH RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARCUATE NUCLEUS; ARTICLE; CLINICAL EVALUATION; CONTROLLED STUDY; DISEASE CLASSIFICATION; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; OPTIC NEURITIS; PRIORITY JOURNAL; RETINA FOVEA; VISUAL ACUITY; VISUAL FIELD; VISUAL FIELD DEFECT; VISUAL IMPAIRMENT;

CONTRAST SENSITIVITY; FOLLOW-UP STUDIES; HUMANS; NERVE FIBERS; OBSERVER VARIATION; OPTIC DISK; OPTIC NEURITIS; PERIMETRY; SCOTOMA; VISUAL ACUITY; VISUAL FIELDS;

EID: 77749319646     PISSN: 00039950     EISSN: 15383601     Source Type: Journal    
DOI: 10.1001/archophthalmol.2010.16     Document Type: Article

References (28)

1. Optic Neuritis Study Group. Visual function 15 years after optic neuritis: a final follow-up report from the Optic Neuritis Treatment Trial [published online November 5, 2007]. Ophthalmology. 2008;115(6):1079.e5- 1082.e5. doi:10.1016/j.ophtha.2007.08.004.
2. Optic Neuritis Study Group. Multiple sclerosis risk after optic neuritis: final Optic Neuritis Treatment Trial follow-up. Arch Neurol. 2008;65(6):727-732.
3. Beck RW, Gal RL. Treatment of acute optic neuritis: a summary of findings from the Optic Neuritis Treatment Trial. Arch Ophthalmol. 2008;126(7):994-995.
4. Volpe NJ. The Optic Neuritis Treatment Trial: a definitive answer and profound impact with unexpected results. Arch Ophthalmol. 2008;126(7):996-999.
5. Keltner JL, Johnson CA, Spurr JO, Beck RW; Optic Neuritis Study Group. Base-line visual field profile of optic neuritis: the experience of the optic neuritis treatment trial. Arch Ophthalmol. 1993;111(2):231-234.
6. Keltner JL, Johnson CA, Spurr JO, Beck RW; Optic Neuritis Study Group. Visual field profile of optic neuritis: 1-year follow-up in the Optic Neuritis Treatment Trial. Arch Ophthalmol. 1994;112(7):946-953.
7. Keltner JL, Johnson CA, Beck RW, Cleary PA, Spurr JO; Optic Neuritis Study Group. Quality control functions of the Visual Field Reading Center (VFRC) for the Optic Neuritis Treatment Trial (ONTT). Control Clin Trials. 1993;14(2):143-159.
8. Keltner JL, Johnson CA, Spurr JO, Beck RW; Optic Neuritis Study Group. Comparison of central and peripheral visual field properties in the Optic Neuritis Treatment Trial. Am J Ophthalmol. 1999;128(5):543-553.
9. Keltner JL, Johnson CA, Quigg JM, Cello KE, Kass MA, Gordon MO; Ocular Hypertension Treatment Study Group. Confirmation of visual field abnormalities in the Ocular Hypertension Treatment Study. Arch Ophthalmol. 2000;118(9): 1187-1194.
10. Johnson CA, Keltner JL, Cello KE, et al; Ocular Hypertension Study Group. Baseline visual field characteristics in the Ocular Hypertension Treatment Study. Ophthalmology. 2002;109(3):432-437.
11. Keltner JL, Johnson CA, Cello KE, et al; Ocular Hypertension Treatment Study Group. Classification of visual field abnormalities in the Ocular Hypertension Treatment Study. Arch Ophthalmol. 2003;121(5):643-650.
12. Keltner JL, Johnson CA, Levine RA, et al; Ocular Hypertension Treatment Study Group. Normal visual field test results following glaucomatous visual field end points in the Ocular Hypertension Treatment Study. Arch Ophthalmol. 2005; 123(9):1201-1206.
13. Keltner JL, Johnson CA, Anderson DR, et al; Ocular Hypertension Treatment Study Group. The association between glaucomatous visual fields and optic nerve head features in the Ocular Hypertension Treatment Study (OHTS). Ophthalmology. 2006;113(9):1603-1612.
14. Keltner JL, Johnson CA, Cello KE, et al; Ocular Hypertension Treatment Study Group. Visual field quality control in the Ocular Hypertension Treatment Study (OHTS). J Glaucoma. 2007;16(8):665-669.
15. Nevalainen J, Krapp E, Paetzold J, et al. Visual field defects in acute optic neuritis: distribution of different types of defect pattern, assessed with threshold-related supraliminal perimetry, ensuring high spatial resolution [published online February 1, 2008]. Graefes Arch Clin Exp Ophthalmol. 2008;246(4): 599-607. doi:10.1007/s00417-007-0722-2.
16. Fang JP, Lin RH, Donahue SP. Recovery of visual field function in the Optic Neuritis Treatment Trial. Am J Ophthalmol. 1999;128(5):566-572.
17. Kupersmith MJ, Gal RL, Beck RW, Xing D, Miller N; Optic Neuritis Study Group. Visual function at baseline and 1 month in acute optic neuritis. Neurology. 2007; 69(6):508-514.
18. Gundogan FC, Demirkaya S, Sobaci G. Is optical coherence tomography really a new biomarker candidate in multiple sclerosis? a structural and functional evaluation. Invest Ophthalmol Vis Sci. 2007;48(12):5773-5781.
19. Cheng H, Laron M, Schiffman J, Tang R, Frishman L. The relationship between visual field and retinal nerve fiber layer measurements in patients with multiple sclerosis. Invest Ophthalmol Vis Sci. 2007;48(12):5798-5805.
20. Cettomai D, Pulicken M, Gordon-Lipkin E, et al. Reproducibility of optical coherence tomography in multiple sclerosis. Arch Ophthalmol. 2008;65(9):1218-1222.
21. Heijl A, Bengtsson B, Chauhan BC, et al. A comparison of visual field progression criteria of 3 major glaucoma trials in Early Manifest Glaucoma Trial patients. Ophthalmology. 2008;115(9):1557-1565.
22. Siger M, Dziegielewski K, Jasek L, et al. Optical coherence tomography in multiple sclerosis: thickness of the retinal nerve fiber layer as a potential measure of axonal loss and brain atrophy. J Neurol. 2008;255(10):1555- 1560. doi:10.1007/s00415-008-0985-5.
23. Watson GM, Keltner JL, Nguyen TG, et al. Comparison of optic nerve and macular thickness among commercially available Fourier-domain and time-domain optical coherence tomography instruments in patients with multiple sclerosis and/or optic neuritis [e-abstract 1530]. Invest Ophthalmol Vis Sci. 2009;50.
24. Trip SA, Schlottmann PG, Jones SJ, et al. Retinal nerve fiber layer axonal loss and visual dysfunction in optic neuritis. Ann Neurol. 2005;58(3):383-391.
25. Gordon-Lipkin E, Chodkowski B, Reich DS, et al. Retinal nerve fiber layer is associated with brain atrophy in multiple sclerosis. Neurology. 2007;69(16):1603-1609.
26. Wu GF, Schwartz ED, Lei T, et al. Relation of vision to global and regional brain MRI in multiple sclerosis. Neurology. 2007;69(23):2128- 2135.
27. Waxman SG, Black JA. Retinal involvement in multiple sclerosis. Neurology. 2007; 69(16):1562-1563.
28. Gerling J, Meyer JH, Kommerell G. Visual field defects in optic neuritis and anterior ischemic optic neuropathy: distinctive features. Graefes Arch Clin Exp Ophthalmol. 1998;236(3):188-192.